EyePoint (EYPT) Is Down 14.2% After Weak Q4 Results And DURAVYU Optimism - What's Changed

Simply Wall St.03-18

EyePoint Pharmaceuticals reported fourth-quarter 2025 revenue of US$620,000 versus US$11.59 million a year earlier, with net loss widening to US$67.61 million and basic loss per share from continuing ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620770574?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-03-18 02:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620770574","market":"sg","top_or_hot":-1,"title":"EyePoint (EYPT) Is Down 14.2% After Weak Q4 Results And DURAVYU Optimism - What's Changed","media":"Simply Wall St.","content":"<div>\n<p>EyePoint Pharmaceuticals reported fourth-quarter 2025 revenue of US$620,000 versus US$11.59 million a year earlier, with net loss widening to US$67.61 million and basic loss per share from continuing ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/eyepoint-eypt-is-down-142-after-weak-q4-results-and-duravyu\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EyePoint (EYPT) Is Down 14.2% After Weak Q4 Results And DURAVYU Optimism - What's Changed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEyePoint (EYPT) Is Down 14.2% After Weak Q4 Results And DURAVYU Optimism - What's Changed\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-18 02:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/eyepoint-eypt-is-down-142-after-weak-q4-results-and-duravyu><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>EyePoint Pharmaceuticals reported fourth-quarter 2025 revenue of US$620,000 versus US$11.59 million a year earlier, with net loss widening to US$67.61 million and basic loss per share from continuing ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/eyepoint-eypt-is-down-142-after-weak-q4-results-and-duravyu\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/eyepoint-eypt-is-down-142-after-weak-q4-results-and-duravyu","article_id":"2620770574","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/eyepoint-eypt-is-down-142-after-weak-q4-results-and-duravyu","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620770574","pubTimestamp":1773771280,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"EyePoint Pharmaceuticals reported fourth-quarter 2025 revenue of US$620,000 versus US$11.59 million a year earlier, with net loss widening to US$67.61 million and basic loss per share from continuing operations rising to US$0.81, while also granting long-term stock options and ending 2025 with cash reportedly sufficient to fund operations into late 2027.\nDespite weaker financial results, investor attention has shifted toward the CEO’s recent purchase of 1,500 shares, analyst optimism linked...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4007":"制药","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","EYPT":"EyePoint"},"translate_title":"由于第四季度业绩疲软和DURAVYU乐观情绪，EyePoint(EYPT)下跌14.2%-发生了什么变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EYPT":1.5},"content_text":"EyePoint Pharmaceuticals reported fourth-quarter 2025 revenue of US$620,000 versus US$11.59 million a year earlier, with net loss widening to US$67.61 million and basic loss per share from continuing operations rising to US$0.81, while also granting long-term stock options and ending 2025 with cash reportedly sufficient to fund operations into late 2027. Despite weaker financial results, investor attention has shifted toward the CEO’s recent purchase of 1,500 shares, analyst optimism linked to favorable safety data for lead asset DURAVYU, and ongoing Phase 3 development that together highlight how expectations around future clinical milestones are increasingly shaping sentiment on the company. Against this backdrop of insider buying and analyst enthusiasm around DURAVYU’s safety profile, we will examine how these developments reshape EyePoint’s investment narrative. The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.AdvertisementEyePoint Investment Narrative RecapTo own EyePoint, you have to believe DURAVYU can eventually convert positive clinical data into approval and meaningful retinal market share, despite today’s very limited revenue and widening losses. The latest quarter’s weak financials and guidance on cash runway do not change the near term focus: Phase 3 DURAVYU readouts and regulatory progress remain the key catalyst, while prolonged minimal revenue and ongoing cash burn tied to this single lead asset stay the central risk. Among the recent announcements, the initiation of Phase 3 COMO and CAPRI trials in diabetic macular edema matters most for the current story. It ties directly to the upcoming DURAVYU data that analysts are watching, and sits alongside the CEO’s share purchase and new employee stock options as signs that the company is organizing itself around those pivotal clinical and, eventually, commercialization milestones. Yet beneath the excitement around DURAVYU, investors should also be aware of the risk that persistent net losses and a limited pipeline could eventually force... Read the full narrative on EyePoint (it's free!)EyePoint's narrative projects $146.7 million revenue and $34.1 million earnings by 2028.Uncover how EyePoint's forecasts yield a $37.08 fair value, a 176% upside to its current price.Exploring Other PerspectivesEYPT 1-Year Stock Price Chart Some of the most optimistic analysts were once modeling EyePoint to reach about US$251 million in revenue and US$58 million in earnings by 2028, which contrasts sharply with the recent sharp revenue drop and wider losses; this more bullish view highlights how differently you and other investors might weigh DURAVYU’s potential versus the real risk of future dilution and how both perspectives may evolve as new data and financial results arrive.Explore 3 other fair value estimates on EyePoint - why the stock might be worth over 7x more than the current price!Reach Your Own ConclusionDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your EyePoint research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.Our free EyePoint research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate EyePoint's overall financial health at a glance.Interested In Other Possibilities?Every day counts. These free picks are already gaining attention. See them before the crowd does:Uncover the next big thing with 33 elite penny stocks that balance risk and reward.Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if EyePoint might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620770574","isCrawlerRequest":true}